Amended Statement of Beneficial Ownership (sc 13d/a)
March 27 2017 - 6:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE 13D
(Amendment No. 2)
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS
FILED PURSUANT
TO § 240.13d-1(a) AND AMENDMENTS
THERETO FILED
PURSUANT TO 240.13d-2(a)
Under the Securities Exchange Act of
1934
Aurinia Pharmaceuticals Inc.
(Name of Issuer)
Common Shares, no par value
(Title of Class of Securities)
05156V102
(CUSIP Number)
ILJIN Life Science Co., Ltd.
(Dohwa-dong), 45 Mapo-daero, Mapo-gu
Seoul, Korea 121-716
+82-2-707-9742
(Name, Address and Telephone Number of
Person Authorized to Receive Notices and Communications)
March
20, 2017
(Date
of Event Which Requires Filing of This St
atement)
If the filing person has previously filed
a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because
of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
¨
The information required on the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended
(the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).
|
CUSIP No. 05156V102
|
|
Page 2 of 7 Pages
|
|
1.
|
|
Name of reporting person
ILJIN Life Science Co., Ltd.
|
|
2.
|
|
Check the appropriate box if a member of a group
(a)
¨
(b)
¨
|
|
3.
|
|
SEC use only
|
|
4.
|
|
Source of funds
WC
|
|
5.
|
|
Check box if disclosure of legal proceedings is required
pursuant to Item 2(e) or 2(f)
¨
|
|
6.
|
|
Citizenship or place of organization
South Korea
|
|
Number of
shares
beneficially
owned by
each
reporting
person
with
|
|
7.
|
|
Sole voting power
0
|
|
|
8.
|
|
Shared voting power
0*
|
|
|
9.
|
|
Sole dispositive power
0
|
|
|
10.
|
|
Shared dispositive power
0*
|
|
11.
|
|
Aggregate amount beneficially owned by each reporting person
0*
|
|
12.
|
|
Check box if the aggregate amount in Row (11) excludes certain
shares
¨
|
|
13.
|
|
Percent of class represented by amount in Row (11)
0%*
|
|
14.
|
|
Type of reporting person
CO
|
|
|
*
|
On March 20, 2017 ILJIN
Life Science Co., Ltd. (“ILJIN Life Science”) transferred its holdings of common shares (“Common Shares”)
of Aurinia Pharmaceuticals Inc. (the “Issuer”) and warrants to purchase Common Shares of the Issuer to ILJIN SNT Co.,
Ltd. (f/k/a Cheoin Leisure Co., Ltd.) (“ILJIN SNT”). ILJIN SNT is the owner of 100% the issued and outstanding common
shares of ILJIN Life Science.
|
|
CUSIP No. 05156V102
|
|
Page 3 of 7 Pages
|
|
1.
|
|
Name of reporting person
ILJIN SNT Co., Ltd.
|
|
2.
|
|
Check the appropriate box if a member of a group
(a)
¨
(b)
¨
|
|
3.
|
|
SEC use only
|
|
4.
|
|
Source of funds
WC
|
|
5.
|
|
Check box if disclosure of legal proceedings is required
pursuant to Item 2(e) or 2(f)
¨
|
|
6.
|
|
Citizenship or place of organization
South Korea
|
|
Number of
shares
beneficially
owned by
each
reporting
person
with
|
|
7.
|
|
Sole voting power
0
|
|
|
8.
|
|
Shared voting power
14,205,457*
|
|
|
9.
|
|
Sole dispositive power
0
|
|
|
10.
|
|
Shared dispositive power
14,205,457*
|
|
11.
|
|
Aggregate amount beneficially owned by each reporting person
14,205,457*
|
|
12.
|
|
Check box if the aggregate amount in Row (11) excludes
certain shares
¨
|
|
13.
|
|
Percent of class represented by amount in Row (11)
17.35%**
|
|
14.
|
|
Type of reporting person
CO
|
|
|
*
|
Consists of: (i) 12,800,038 Common Shares of the Issuer
held by ILJIN SNT; and (ii) 1,405,419 Common Shares issuable to ILJIN SNT upon the exercise of outstanding warrants that are exercisable
within 60 days.
|
|
|
**
|
Based on: (i) 80,456,243 Common Shares issued and outstanding as of March 20, 2017, as reported to the Reporting Persons by
the Issuer, plus (ii) 1,405,419 Common Shares underlying warrants held by ILJIN SNT that are exercisable within 60 days which are
treated as issued and outstanding only for the purpose of computing the percentage ownership of ILJIN SNT pursuant to Rule 13d-3(d)(1)(i)
under the Act.
|
|
CUSIP No. 05156V102
|
|
Page 4 of 7 Pages
|
|
1.
|
|
Name of reporting person
Chin Kyu Huh
|
|
2.
|
|
Check the appropriate box if a member of a group
(a)
¨
(b)
¨
|
|
3.
|
|
SEC use only
|
|
4.
|
|
Source of funds
OO – other
|
|
5.
|
|
Check box if disclosure of legal proceedings is required
pursuant to Item 2(e) or 2(f)
¨
|
|
6.
|
|
Citizenship or place of organization
South Korea
|
|
Number of
shares
beneficially
owned by
each
reporting
person
with
|
|
7.
|
|
Sole voting power
0
|
|
|
8.
|
|
Shared voting power
14,205,457*
|
|
|
9.
|
|
Sole dispositive power
0
|
|
|
10.
|
|
Shared dispositive power
14,205,457*
|
|
11.
|
|
Aggregate amount beneficially owned by each reporting person
14,205,457*
|
|
12.
|
|
Check box if the aggregate amount in Row (11) excludes
certain shares
¨
|
|
13.
|
|
Percent of class represented by amount in Row (11)
17.35%**
|
|
14.
|
|
Type of reporting person
IN
|
|
|
*
|
Consists of: (i) 12,800,038 Common Shares of the Issuer
held by ILJIN SNT; and (ii) 1,405,419 Common Shares issuable to ILJIN SNT upon the exercise of outstanding warrants that are exercisable
within 60 days.
|
|
|
**
|
Based on: (i) 80,456,243 Common Shares issued and outstanding
as of March 20, 2017, as reported to the Reporting Persons by the Issuer, plus (ii) 1,405,419 Common Shares underlying warrants
held by ILJIN SNT that are exercisable within 60 days which are treated as issued and outstanding only for the purpose of computing
the percentage ownership of Mr. Huh pursuant to Rule 13d-3(d)(1)(i) under the Act.
|
|
CUSIP No. 05156V102
|
|
Page 5 of 7 Pages
|
|
ITEM 1.
|
SECURITIES AND ISSUER.
|
This
Amendment No. 2 (the “Amendment”) to Schedule 13D is being filed with the Securities & Exchange Commission
(the “SEC”) on behalf of (i) ILJIN Life Science Co., Ltd. (“ILJIN Life Science”); (ii) ILJIN
SNT Co., Ltd. (f/k/a Cheoin Leisure Co., Ltd.) (“ILJIN SNT”); and (iii) Chin Kyu Huh (each, a “Reporting
Person”, and collectively, the “Reporting Persons”), relating to the common shares, no par value (the
“Common Shares”), of Aurinia Pharmaceuticals Inc. (the “Issuer”). This Amendment amends and
supplements the initial statement on Schedule 13D (the “Original Schedule 13D”) filed by the Reporting Persons
with the SEC on July 5, 2016 and Amendment No. 1 to the Original Schedule 13D (“Amendment No. 1”) filed by the
Reporting Persons with the SEC on January 5, 2017. Except as set forth herein, this Amendment does not modify any of the
information previously reported by the Reporting Persons in the Original Schedule 13D or Amendment No. 1. Unless otherwise
indicated, all capitalized terms used herein have the meanings ascribed to them in the Original Schedule 13D or Amendment No.
1.
|
ITEM 2.
|
IDENTITY AND BACKGROUND.
|
|
(a) – (b)
|
The Common Shares that may be deemed to be beneficially owned
by each Reporting Person are set forth on Line 11 of such Reporting Person’s cover sheet and in Item 5 below. ILJIN SNT is
the owner of 100% the issued and outstanding common shares of ILJIN Life Science. Mr. Huh is the indirect owner of 100% of the
issued and outstanding common shares of ILJIN SNT. Mr. Huh is the Chief Executive Officer and a director of ILJIN Life Science.
Mr. Huh is responsible for voting and dispositive decisions of ILJIN Life Science and ILJIN SNT. Accordingly, Mr. Huh may be deemed
to have investment and voting control over the Common Shares held by ILJIN Life Science and ILJIN SNT.
|
|
ITEM 3.
|
SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.
|
On March 20, 2017, the Issuer closed its previously announced
US$173.1 million public offering of 25,645,000 Common Shares (including 3,345,000 Common Shares pursuant to an exercise of the
underwriter’s over-allotment option) of the Issuer at a price of US$6.75 per Common Share (the “Offering”). ILJIN
SNT acquired 5,185,185 Common Shares in the Offering, for a total purchase price of US$34,999,998.75. The source used to make the
purchase was funds available to ILJIN SNT from cash on hand.
|
CUSIP No. 05156V102
|
|
Page 6 of 7 Pages
|
|
ITEM 5.
|
INTEREST IN SECURITIES OF THE ISSUER.
|
|
(a) – (b)
|
The aggregate number of Common Shares beneficially owned by
ILJIN Life Science as of the date hereof is 0. On March 20, 2017 ILJIN Life Science transferred its holdings of Common Shares and
warrants to purchase Common Shares to ILJIN SNT.
The aggregate number of Common Shares beneficially owned by
ILJIN SNT as of the date hereof is 14,205,457. This consists of: (i) 12,800,038 Common Shares of the Issuer held by ILJIN SNT;
and (ii) 1,405,419 Common Shares issuable to ILJIN SNT upon the exercise of outstanding warrants that are exercisable within 60
days.
The aggregate number of Common Shares beneficially owned by
Mr. Huh as of the date hereof is14,205,457. This consists of: (i) 12,800,038 Common Shares of the Issuer held by ILJIN SNT; and
(ii) 1,405,419 Common Shares issuable to ILJIN SNT upon the exercise of outstanding warrants that are exercisable within 60 days.
Mr. Huh is the indirect owner of 100% of the issued and outstanding common shares of ILJIN SNT. Mr. Huh is responsible for voting
and dispositive decisions of ILJIN SNT. Accordingly, Mr. Huh may be deemed to have investment and voting control over the Common
Shares and Warrants held by ILJIN SNT. Mr. Huh does not directly own any Common Shares or Warrants of the Issuer.
The percentage of outstanding Common Shares that may
be deemed to be beneficially owned by each Reporting Person is set forth on line 13 of the cover sheet of this Amendment. Such
percentage was calculated based on (i) 80,456,243 Common Shares issued and outstanding as of March 20, 2017, as reported to the
Reporting Persons by the Issuer, plus (ii) the number of Common Shares issuable to each Reporting Person upon the exercise of
outstanding warrants that are exercisable within 60 days.
Except as disclosed in this Amendment, none of the Reporting
Persons beneficially owns any Common Shares or has the right to acquire any Common Shares or Warrants.
|
|
(c)
|
The reported share amounts for the Reporting Persons reflect amounts as of the date hereof. Other than pursuant to the Offering, the Reporting Persons have not effected any transactions in the Common Shares or Warrants during the past 60 days.
|
|
(d)
|
To the best knowledge of the Reporting Persons, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Shares or Warrants beneficially owned by the Reporting Persons.
|
|
|
|
|
(e)
|
Not applicable.
|
|
CUSIP No. 05156V102
|
|
Page 7 of 7 Pages
|
SIGNATURE
After reasonable inquiry and to the best
of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.
Dated: March 24, 2017
|
|
/s/ Chin Kyu Huh
|
|
|
Chin Kyu Huh
|
|
|
|
|
|
ILJIN LIFE SCIENCE CO., LTD.
|
|
|
|
|
|
By:
|
/s/ Chin Kyu Huh
|
|
|
|
Name: Chin Kyu Huh
|
|
|
|
Title: Chief Executive Officer
|
|
|
|
|
|
|
|
|
|
|
ILJIN SNT CO., LTD.
|
|
|
|
|
|
By:
|
/s/ Gyu Oan Choi
|
|
|
|
Name: Gyu Oan Choi
|
|
|
|
Title: Chief Executive Officer
|
|
|
|
|
|
|
|
|
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Apr 2023 to Apr 2024
